Skip to content
Triangle logo TriangleGet started
← Melanoma

HEALTH PROFESSIONAL · SOURCE READING

Trametinib

Source: Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 2, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment Option Overview for Melanoma / Systematic Treatment for Unresectable Stage III, Stage IV, and Recurrent Disease / Signal transduction inhibitors / MEK inhibitors

Trametinib is an orally available, small-molecule, selective inhibitor of MEK1 and MEK2. The FDA approved trametinib in 2013 for patients with unresectable or metastatic melanoma with BRAF V600E or V600K pathogenic variants. Trametinib demonstrated improved PFS when compared with dacarbazine.[28]

Source links and citations

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice